Results for “”

Entry Author Date Location
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus 01/29/20 Boston
Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH 01/28/20 Boston
Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report 01/28/20 National
Flagship Adds Fertility-Focused Ohana Biosciences to Biotech Family 01/27/20 Boston
Quench Bio Springs From Atlas With $50M for a New Take on Inflammation 01/27/20 Boston
Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More 01/24/20 National
Epizyme’s Soft Tissue Cancer Drug Granted Speedy FDA Approval 01/23/20 Boston
FDA Flags Risk of Infection, Kidney Damage for Sarepta Duchenne Drugs 01/22/20 Boston
Emendo Eyes the Clinic for CRISPR Therapy That Makes Single-Gene Edits 01/22/20 New York
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers 01/17/20 San Francisco
Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More 01/17/20 National
Cancer Drug Developer BioNTech to Buy Neon Therapeutics in $67M Deal 01/16/20 Boston
FDA Panel Votes Down Nektar Opioid Painkiller, Asks for More Data 01/14/20 National
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline 01/14/20 New York
Generation Bio Pockets $110M for Next Wave of Gene Therapy, IPO Plans 01/13/20 Boston
Biotech Roundup: Drug Pricing Promises, Bone Disease Data, IPO Plans & More 01/10/20 National
Biogen Teams Up With Startup CAMP4 to Scout for New Neuro Drugs 01/10/20 Boston
Solid Bio Restructures to Get Halted Gene Therapy Study Back on Track 01/09/20 Boston
Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy 01/08/20 San Francisco
Apellis Rare Blood Disease Drug Tops Alexion’s in Head-to-Head Test 01/07/20 Boston
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic 01/07/20 Boston
Merck Ramps Up KRAS Chase Through Licensing Deal With Taiho, Astex 01/06/20 New York
Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More 01/03/20 National
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal 12/23/19 Boston
Biogen Strikes Alzheimer’s Deal, Paying $45M for Ionis Tau Drug Rights 12/19/19 San Diego
Ring Therapeutics Launches to Expand Gene Therapy Viral Vector Options 12/19/19 Boston
Zafgen’s Path Forward Is Reverse Merger With Chondrial Therapeutics 12/18/19 Boston
Triplet Therapeutics Unveils $59M to Try Hairpin Fix for Huntington’s 12/17/19 Boston
Organovo’s Demise Offers Path for Tarveda to Join the Public Markets 12/16/19 San Diego
Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More 12/13/19 National
Page 1 of 135 next page »